529 related articles for article (PubMed ID: 33710439)
1. Monitoring serum estradiol levels in breast cancer patients during extended adjuvant letrozole treatment after five years of tamoxifen: a prospective trial.
Faltinová M; Vehmanen L; Lyytinen H; Haanpää M; Hämäläinen E; Tiitinen A; Blomqvist C; Mattson J
Breast Cancer Res Treat; 2021 Jun; 187(3):769-775. PubMed ID: 33710439
[TBL] [Abstract][Full Text] [Related]
2. Effects of letrozole on serum estradiol and estrone in postmenopausal breast cancer patients and tolerability of treatment: a prospective trial using a highly sensitive LC-MS/MS (liquid chromatography-tandem mass spectrometry) method for estrogen measurement.
Faltinová M; Vehmanen L; Lyytinen H; Haanpää M; Hämäläinen E; Tiitinen A; Blomqvist C; Mattson J
Breast Cancer Res Treat; 2023 Oct; 201(3):425-435. PubMed ID: 37491651
[TBL] [Abstract][Full Text] [Related]
3. Superior suppression of serum estrogens during neoadjuvant breast cancer treatment with letrozole compared to exemestane.
Bertelsen BE; Almås B; Fjermeros K; Viste K; Geisler SB; Sauer T; Selsås K; Geisler J
Breast Cancer Res Treat; 2024 Jul; 206(2):347-358. PubMed ID: 38649619
[TBL] [Abstract][Full Text] [Related]
4. Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer.
Dixon JM; Renshaw L; Young O; Murray J; Macaskill EJ; McHugh M; Folkerd E; Cameron DA; A'Hern RP; Dowsett M
J Clin Oncol; 2008 Apr; 26(10):1671-6. PubMed ID: 18375896
[TBL] [Abstract][Full Text] [Related]
5. Measurable Serum Estradiol and Estrone in Women 36-56 Years During Adjuvant Treatment With Aromatase Inhibitors for a Hormone Receptor-Positive Breast Cancer. Case Studies and Cross-sectional Study Using an Ultra-sensitive LC-MS/MS-Method.
Van Houdt M; Han SN; Pauwels S; Billen J; Neven P
Clin Breast Cancer; 2023 Jan; 23(1):84-90. PubMed ID: 36376236
[TBL] [Abstract][Full Text] [Related]
6. Hormonal therapies for early breast cancer: systematic review and economic evaluation.
Hind D; Ward S; De Nigris E; Simpson E; Carroll C; Wyld L
Health Technol Assess; 2007 Jul; 11(26):iii-iv, ix-xi, 1-134. PubMed ID: 17610808
[TBL] [Abstract][Full Text] [Related]
7. Simultaneous Quantification of Aromatase Inhibitors and Estrogens in Postmenopausal Breast Cancer Patients.
Bertelsen BE; Viste K; Helland T; Hagland M; Søiland H; Geisler J; Lende TH; Lønning PE; Sagen JV; Mellgren G; Almås B
J Clin Endocrinol Metab; 2022 Apr; 107(5):1368-1374. PubMed ID: 34958096
[TBL] [Abstract][Full Text] [Related]
8. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
Jahanzeb M
Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
[TBL] [Abstract][Full Text] [Related]
9. Effects of exemestane and letrozole therapy on plasma concentrations of estrogens in a randomized trial of postmenopausal women with breast cancer.
Robarge JD; Desta Z; Nguyen AT; Li L; Hertz D; Rae JM; Hayes DF; Storniolo AM; Stearns V; Flockhart DA; Skaar TC; Henry NL
Breast Cancer Res Treat; 2017 Feb; 161(3):453-461. PubMed ID: 27943008
[TBL] [Abstract][Full Text] [Related]
10. Higher than expected estradiol levels in aromatase inhibitor-treated, postmenopausal breast cancer patients.
Kunovac Kallak T; Baumgart J; Stavreus Evers A; Sundström Poromaa I; Moby L; Kask K; Norjavaara E; Kushnir MM; Bergquist J; Nilsson K
Climacteric; 2012 Oct; 15(5):473-80. PubMed ID: 22324859
[TBL] [Abstract][Full Text] [Related]
11. The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L).
Wasan KM; Goss PE; Pritchard PH; Shepherd L; Palmer MJ; Liu S; Tu D; Ingle JN; Heath M; Deangelis D; Perez EA
Ann Oncol; 2005 May; 16(5):707-15. PubMed ID: 15817595
[TBL] [Abstract][Full Text] [Related]
12. Emerging role of aromatase inhibitors in the adjuvant setting.
Goss PE
Am J Clin Oncol; 2003 Aug; 26(4):S27-33. PubMed ID: 12902874
[TBL] [Abstract][Full Text] [Related]
13. Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer.
Berry J
Clin Ther; 2005 Nov; 27(11):1671-84. PubMed ID: 16368441
[TBL] [Abstract][Full Text] [Related]
14. Variable aromatase inhibitor plasma concentrations do not correlate with circulating estrogen concentrations in post-menopausal breast cancer patients.
Hertz DL; Speth KA; Kidwell KM; Gersch CL; Desta Z; Storniolo AM; Stearns V; Skaar TC; Hayes DF; Henry NL; Rae JM
Breast Cancer Res Treat; 2017 Oct; 165(3):659-668. PubMed ID: 28643023
[TBL] [Abstract][Full Text] [Related]
15. Letrozole: a pharmacoeconomic review of its use in postmenopausal women with breast cancer.
Dunn C; Keam SJ
Pharmacoeconomics; 2006; 24(5):495-517. PubMed ID: 16706574
[TBL] [Abstract][Full Text] [Related]
16. Design, conduct, and analyses of Breast International Group (BIG) 1-98: a randomized, double-blind, phase-III study comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive, early breast cancer.
Giobbie-Hurder A; Price KN; Gelber RD; ;
Clin Trials; 2009 Jun; 6(3):272-87. PubMed ID: 19528136
[TBL] [Abstract][Full Text] [Related]
17. The use of early adjuvant aromatase inhibitor therapy: contributions from the BIG 1-98 letrozole trial.
Forbes JF
Semin Oncol; 2006 Apr; 33(2 Suppl 7):S2-7. PubMed ID: 16730270
[TBL] [Abstract][Full Text] [Related]
18. Incidence and Predictive Factors for Recovery of Ovarian Function in Amenorrheic Women in Their 40s Treated With Letrozole.
Krekow LK; Hellerstedt BA; Collea RP; Papish S; Diggikar SM; Resta R; Vukelja SJ; Holmes FA; Reddy PK; Asmar L; Wang Y; Fox PS; Peck SR; O'Shaughnessy J
J Clin Oncol; 2016 May; 34(14):1594-600. PubMed ID: 26884554
[TBL] [Abstract][Full Text] [Related]
19. An Ultrasensitive Routine LC-MS/MS Method for Estradiol and Estrone in the Clinically Relevant Sub-Picomolar Range.
Bertelsen BE; Kellmann R; Viste K; Bjørnevik AT; Eikesdal HP; Lønning PE; Sagen JV; Almås B
J Endocr Soc; 2020 Jun; 4(6):bvaa047. PubMed ID: 32500111
[TBL] [Abstract][Full Text] [Related]
20. Changing clinical practice: extending the benefits of adjuvant endocrine therapy in breast cancer.
Goss PE
Semin Oncol; 2004 Dec; 31(6 Suppl 12):15-22. PubMed ID: 15719597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
